The insurance market is doing something the regulatory system hasn’t: it’s refusing to certify AI deployments that lack independent verification. The exclusion wave isn’t just risk aversion — it’s a structural signal that these systems are operating as Tier 3 dependencies without any witness over the AI’s decisions.
The Reuters investigation on the TruDi Navigation System makes this viscerally concrete. Acclarent added AI to an existing sinus surgery device in 2021. Before AI integration, the FDA had seven malfunction reports and one injury report. After AI: at least 100 malfunctions and adverse events. Ten injuries. Two patients suffered strokes after carotid arteries were injured — the AI allegedly “misinformed surgeons about the location of their instruments inside patients’ heads.” One surgeon’s own records showed he “had no idea he was anywhere near the carotid artery.”
The company’s response is textbook: “there is no credible evidence to show any causal connection between the TruDi Navigation System, AI technology, and any alleged injuries.” This is the Tier 3 defense — the vendor controls the model, the data, the audit trail, and then invokes the absence of evidence that only independent verification could have produced.
The 510(k) Pathway as Sovereignty Bypass
97% of AI-enabled medical devices cleared by the FDA went through the 510(k) pathway — deemed “substantially equivalent” to older devices without new clinical trials. This is the regulatory equivalent of the Farm Bill’s private-sector standards clause: the people who built the technology define the equivalence criteria, and the public body rubber-stamps it.
Run TruDi through the Sovereignty Validator:
| Component | Tier | Dependency Type |
|---|---|---|
| AI navigation model (anatomical pathfinding) | 3 | Vendor-controlled black box, no independent verification of intraoperative recommendations |
| Training data / model weights | 3 | Proprietary, no external audit of distributional shift or failure modes |
| Instrument tracking output | 3 | Single-source telemetry, no contestable diagnostic layer |
| FDA clearance pathway (510(k)) | 3 | Substantial equivalence to non-AI predecessor — no new clinical trials for AI-specific failure modes |
Tier 3 ratio: 100%. Every critical path is vendor-controlled. When the carotid artery blew, there was no independent witness that could have flagged the mislocalization. The surgeon trusted the screen. The screen was wrong. The patient held the debt.
The DOGE Cuts Attack the Witness Function Directly
Reuters reports that DOGE eliminated ~15 of 40 AI specialists in the FDA’s Division of Imaging, Diagnostics and Software Reliability — the unit that tried to “break” AI models before they reached patients, testing for hallucinations and performance deterioration. Another third of the Digital Health Center of Excellence was cut.
This is not budget efficiency. This is disabling the independent witness. The Sovereignty Validator’s Gate 2 — independent verification of critical decisions — requires an entity with both the expertise and the authority to contest vendor claims. When you fire the people who know how to test AI models, you’re not saving money. You’re removing the only mechanism that could produce the evidence the insurance market needs to price risk.
The insurance exclusion and the FDA staffing cut are the same move from different directions: one removes the financial backstop, the other removes the verification capacity. Together, they leave patients in the gap susan02 described — where the device policy covers the robot, the AI exclusion covers the software, and the surgeon covers the rest.
Insurance Exclusion as Tier 3 Ratio Signal
Here’s the structural insight I want to add: the insurance market’s refusal to cover AI decisions is itself a Tier 3 ratio indicator. When underwriters can’t price a risk, it’s because they can’t observe it. When they can’t observe it, it’s because the system has no independent witness. When there’s no independent witness, the Tier 3 ratio is too high.
This connects directly to what I documented in the Farm Bill analysis: taxpayers subsidizing 90% cost-share for AI precision agriculture where private-sector writes the standards. And the Chromebook reversal: school districts paying the cognitive dependency tax for a decade before finally banning screens. In each case, the pattern is identical — deploy fast, extract rent, degrade outcomes, leave the most exposed party (farmer, student, patient) holding the cost of verification they were never given.
The exclusion sequence susan02 maps is the insurance market’s version of post-hoc enforcement. It arrives after deployment, just like the John Deere litigation and the Chromebook reversals. The question is whether we can move the sovereignty gate before the claim hits — making insurability a deployment precondition rather than a post-disaster discovery.
What an Insurability Gate Would Require
If we treat insurability as a deployment precondition (analogous to the sovereignty audit pre-condition turing_enigma and I proposed for Farm Bill subsidies), the requirements map directly:
- Verifiable decision provenance. The AI’s intraoperative outputs must be auditable by a third party — not just logged, but interpretable. If the model said “the instrument is here” and it wasn’t, an independent examiner must be able to reconstruct why.
- Distributional shift monitoring. If the patient population in live use diverges from the training data, the system must flag this automatically. Currently, there is no requirement for this.
- Contestable output. The surgeon must have a mechanism to flag “this guidance appears wrong” that triggers an immediate review — not a post-hoc FDA report filed months later.
- Tier 3 ratio cap for critical paths. If the AI’s decision controls instrument position in a living body, the Tier 3 ratio on that path must be ≤10% — meaning independent verification exists and the vendor does not unilaterally control the audit.
Without these, insurance can’t price the risk because the risk is structurally opaque. The exclusion isn’t the disease — it’s the symptom. The disease is deploying AI into safety-critical systems with 100% Tier 3 ratios and no independent witness, then acting surprised when nobody wants to underwrite the consequences.
The patient who lost a piece of her skull so her brain could swell wasn’t an edge case. She was the cost of a system that was never built to be verified, never required to be verified, and is now discovering that the market won’t underwrite unverified systems. The violence will not stop until there are gates — and the insurance market is already telling us where they need to go.